Welcome back to the journal review. This is your walkthrough of the August twenty twenty-six issue of the Journal of the American Academy of Dermatology — four pieces this time, ranging from a dermoscopy correspondence exchange, to a multidisciplinary surgical case series, to a SEER-based epidemiology study, and closing with an ethics column on generative artificial intelligence in our visual specialty. Let's get into it.

First up is a letter — specifically, an authors' response in an ongoing correspondence thread about ultraviolet-induced fluorescent dermoscopy, or UVFD, and its "ochre color" sign in melanoma. You'll recall the original multicenter study from this same group proposed that a brown-golden-yellow fluorescence, visible only under UV illumination and not under naked eye or polarized light, correlates with invasive melanoma. A prior letter from Mart and Akay pushed back, noting they'd observed this ochre color in an atypical Spitz tumor — raising the question of whether the sign is melanoma-specific at all. This response doesn't back down but does sharpen the claim considerably. The authors say they're not surprised that ochre color can appear in atypical Spitz tumors, and they explicitly say this finding doesn't invalidate the sign — they draw a direct analogy to shiny white lines under polarized dermoscopy, a well-accepted marker of invasion in melanoma that is also known to occasionally appear in Spitz tumors and various benign lesions like traumatized nevi and dermatofibromas. The logic being: an imperfect specificity for melanoma across the entire universe of melanocytic lesions doesn't kill a sign's clinical utility if, within melanoma itself, its presence tracks with a clinically important feature — here, invasion and Breslow depth. They also cite a newer multicenter study of two hundred thirty-four lesions that reinforces this: ochre color does turn up in a small subset of benign melanocytic lesions — dysplastic nevi, junctional nevi, melanocytic tumors of uncertain malignant potential — but among melanomas specifically, its presence was significantly tied to invasive disease and greater thickness. Critically, they stress it has never been observed in a nonmelanocytic lesion, and they push back on the letter's actual image, arguing what was shown was green fluorescence limited to skin creases, not true ochre color, which they insist occurs as homogeneous intratumoral areas rather than following skin folds. This is a definitional clarification as much as a scientific rebuttal. There's no new data generation here — this is correspondence, so there's no methods or limitations section to walk through. But the practical thread that matters to you as a proceduralist is explicit and repeated across both this letter and the parent studies: when ochre color is seen, even in a clinically flat melanocytic lesion, it should raise your index of suspicion for an invasive component and may argue for a full-thickness excisional biopsy rather than a shallow saucerization or shave — a genuinely actionable biopsy-planning pearl, even while the sign itself remains unvalidated as an independent stand-alone diagnostic criterion.

Second, a case series describing what the authors call Mohs-facilitated excision — a multidisciplinary strategy for high-risk keratinocyte carcinomas where Mohs surgery is anticipated, going in, to be unable to achieve clear margins under local anesthesia. This is a retrospective case series pulled from a prospectively maintained single-institution Mohs database spanning some seventeen years. The design logic is straightforward and the authors are explicit about it: rather than waiting for an incomplete Mohs surgery to happen unexpectedly and then scrambling for a salvage plan, they proactively identified cases where clearance would likely be blocked by invasion of bone, critical anatomy resistant to local excision, or major neurovascular structures — and built a preoperative multidisciplinary plan so the Mohs surgeon could clear tumor right up to that critical structure, tag and map the residual disease, and hand off to a surgical colleague for definitive excision under general anesthesia in the same care episode. There's no comparative statistical modeling here — this is a descriptive case series with Kaplan-Meier estimation used just for one purpose, generating a three-year local recurrence estimate with a confidence interval that appropriately accounts for variable follow-up time and censoring, since not every patient had reached three years by the time of analysis. That's really the whole statistical toolkit in play, and it's the right one for a small single-arm cohort with incomplete follow-up.

Fifty-nine tumors met criteria — mostly large, recurrent, head and neck lesions with a very high rate of documented perineural invasion, over half the cohort. Periosteal or bone invasion was overwhelmingly the reason Mohs was expected to fall short, accounting for about two-thirds of cases, notably higher than the fourteen to twenty-nine percent range reported in prior incomplete-Mohs literature — the authors attribute this to their referral pattern and threshold for enrollment. Otolaryngology was involved in nearly two-thirds of cases, plastics in about a third, radiation oncology in over a third. The bottom line result: despite anticipating incomplete Mohs surgery in every single patient by design, final microscopic margin clearance was achieved in about eighty-five percent after the coordinated excision. Local recurrence was low, around three percent, and metastasis occurred in roughly seven percent over an average follow-up of a bit over two years. The three-year Kaplan-Meier local recurrence estimate came out around four percent. What's notable is this was achieved with a lower adjuvant radiation rate than comparable incomplete-Mohs cohorts in the literature — about thirty-six percent here versus thirty-five to sixty percent elsewhere — suggesting the improved outcome is coming from the surgical coordination itself and not simply from more aggressive adjuvant treatment. The authors are appropriately humble about limitations: single institution with an unusually rich multidisciplinary bench, variable and relatively short follow-up, no power to compare adjuvant strategies head to head, and no true control arm of unanticipated incomplete Mohs cases treated without this proactive pathway. Practically, this is genuinely useful for anyone doing high-volume head and neck Mohs surgery on advanced disease: the actionable takeaway isn't a new technique per se, it's a workflow — build the preoperative multidisciplinary conversation and general anesthesia backup plan before you start Mohs surgery on a tumor you already suspect will hit bone or a major nerve, rather than improvising after the fact. That anticipatory coordination, not any single technical maneuver, appears to be what's driving the low recurrence rate.

Third is a population-based descriptive retrospective cohort study using SEER data, examining whether rurality's association with melanoma incidence differs across race and ethnicity — a question the authors note has been underexplored because most rural-urban melanoma work hasn't stratified by racial and ethnic group at a national level. They pulled close to four hundred ninety thousand melanoma cases from SEER registries and calculated incidence rates and incidence rate ratios comparing rural to urban residence within each racial and ethnic group. It's worth pausing on the statistic here because it's genuinely the right tool for this data structure. An incidence rate ratio is not the same computation as a simple risk ratio from a cohort with a fixed denominator of individuals — it's built from population-level incidence rates, cases divided by person-time or population size in each stratum, which is exactly what registry data like SEER gives you, since you don't have individual-level follow-up on every person in the population, only the numerator of diagnosed cases and denominator population counts. Comparing those rates as a ratio, with confidence intervals derived from the underlying case counts, lets you say a rural population's melanoma incidence is some multiple of the urban population's, adjusting for the fact that the two groups are different sizes — but it's important to flag, as the authors themselves do, that this is inherently a descriptive, ecological comparison; it can't adjust for individual-level confounders like sun exposure, skin type, or insurance status the way a matched cohort or regression model could.

The results: non-Hispanic White patients made up the overwhelming majority of cases, about ninety-five percent of the cohort, and for this group rural incidence was significantly lower than urban, an incidence rate ratio of point eight four. Non-Hispanic Black patients showed a modest but statistically significant higher rural incidence overall, around an eighteen percent relative increase, though this didn't hold up consistently when broken down by stage, and the authors are careful to call this a small effect without a clear stage-specific pattern — a nice example of a statistically significant but clinically marginal finding. The standout result is among non-Hispanic Asian or Pacific Islander patients, where rural incidence was two and a half times higher than urban — a striking reversal of the pattern seen in every other group, and one the authors flag as not widely reported before. Non-Hispanic American Indian and Alaska Native patients had the second-highest overall incidence behind non-Hispanic White patients, though this group is historically prone to undercounting and misclassification in registry data, which the authors explicitly caution about. Hispanic patients showed no significant rural-urban difference. The limitations here are substantial and honestly stated: small rural sample sizes for every non-White group make those estimates unstable, there's no individual socioeconomic or insurance data, rurality was classified only as an ordinal category without finer geographic resolution, and there was no spatial autocorrelation analysis. So this is hypothesis-generating, not causally definitive. For your practice, this isn't practice-changing in the sense of altering how you manage a patient in front of you, but it is a signal worth carrying into how you think about outreach and triage — particularly that unexpected non-Hispanic Asian or Pacific Islander rural incidence finding, which combined with previously documented delays to surgery in this population, suggests a real access or risk-perception gap that dermatologic workforce distribution and tele-dermatology efforts should be targeting, rather than assuming rural melanoma risk is a uniformly White, sun-exposure-driven phenomenon.

Last is an ethics column, framed as a "Dear Dr Dermatoethicist" advice letter, addressing accountability for AI-generated dermatologic images and content. There's no study design here, so no methods or results to walk through — this is a normative argument, and it's worth hearing in full because it's squarely relevant to a visually anchored specialty like ours. The core observation is that generative tools — the column names DermGAN and S-SYNTH specifically — can now produce synthetic clinical images that dermatologists themselves struggle to distinguish from real photographs, and that these are already leaking into training datasets, social media, and educational material, often without any disclosure. The column cites a striking demonstration where investigators used publicly available generative tools to produce targeted health disinformation blogs, synthetic images, and a convincing deepfake video of a clinician, all within hours — meant to underscore that this isn't a hypothetical future risk. It also flags that systematic reviews of AI-powered dermatology apps show widespread unsubstantiated diagnostic claims with little regulatory clearance or validation behind them. The ethical framing runs through the classic principles: non-maleficence, because unlabeled synthetic content risks delayed diagnosis or false reassurance if patients or clinicians mistake it for real clinical data; autonomy, because patients and learners can't meaningfully consent to or evaluate content they don't know is synthetic — the column specifically calls out fabricated before-and-after treatment images as a concrete risk; and justice, because people with lower digital literacy are disproportionately vulnerable to being misled by polished synthetic content. The authors do offer a constructive middle path rather than a call for prohibition — generative tools have a legitimate role for standardized illustration and clearly labeled simulation-based teaching, and they specifically caution that skin-tone underrepresentation in image datasets should be fixed by collecting more real diverse clinical images, not by generating synthetic diversity. They also note emerging evidence that natural-language-processing tools can flag health misinformation with good accuracy, meaning AI can be part of the defense as well as the problem. The accountability they call for is distributed across the whole ecosystem: clinicians and educators modeling transparent AI use and teaching AI literacy to trainees, journals mandating disclosure and adopting tools like embedded metadata or watermarking to flag AI-generated images, and platforms acknowledging their role in amplifying this content. There's no data here to caveat, so the practical takeaway is more cultural than procedural — if you're presenting cases, teaching, or publishing images and you've used any generative or AI-assisted tool anywhere in that pipeline, disclose it explicitly, and treat unlabeled "before-and-after" or clinical images circulating online with real skepticism, because the visual authority dermatology has spent decades building is exactly what's now exploitable.

That wraps this episode. To summarize the actionable threads: the ochre-color debate sharpens rather than weakens the case for full-thickness biopsy when that sign is seen in a flat melanocytic lesion; the Mohs-facilitated excision series is a genuinely practice-informing workflow argument for anticipatory multidisciplinary planning in high-risk head and neck tumors likely to hit bone or major nerves; the SEER rurality data is hypothesis-generating, with the Asian and Pacific Islander rural incidence finding the one worth watching most closely; and the AI ethics piece is a call to build disclosure habits now, before synthetic content further erodes trust in the images our whole specialty runs on. Thanks for listening, and I'll see you next issue.